Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301246 | 0.71 | NPC1 (0.41) | GABRA1GABRG2GABRB3GABRA3NPC1 | |
| SCHEMBL3818919 | 0.69 | MEN1 (0.34) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1456870 | 0.67 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30538677 | 0.67 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7297879 | 0.67 | SPR (0.34) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL19371050 | 0.60 | TSHR (0.31) | — | |
| SCHEMBL19371085 | 0.59 | NPC1 (0.33) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL22138703 | 0.59 | SPR (0.32) | NPC1RAB9A | |
| SCHEMBL728744 | 0.59 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5353345 | 0.58 | GABRA1 (0.31) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598192-B2 | Hydroxylamine substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-12-03 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1682544-A4 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| EP-1685129-A4 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1682544-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105295-A1 | HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES | IL2, IL4, IFNG | GABRA1 1925/4885GABRG2 2099/4885GABRB3 1918/4885 |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | GABRA1 2056/4885GABRG2 1859/4885GABRB3 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.